SCHEMBL19559734

SCHEMBL19559734

CCC1=CC=C([C@@H](COc2ccc(CC3SC(=O)N(N)C3=O)cc2)OC(C)=O)NC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 14/20 0.36
▸ HTT P42858 1/20 0.33
▸ MPC2 O95563 1/20 0.32
▸ CYP2C8 P10632 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ MCL1 Q07820 1/20 0.31
▸ CYP3A4 P08684 2/20 0.30
▸ RXRA P19793 1/20 0.30
▸ ESR1 P03372 1/20 0.30
▸ ALDH1A1 P00352 2/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19559716 0.77 PPARG (0.40) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL19217715 0.77 PPARG (0.41) PPARGHTTMPC2CYP2C8CYP2C9
SCHEMBL19217746 0.76 PPARG (0.49) PPARGMPC2CYP2C8CYP2C9CYP3A4
SCHEMBL19559701 0.75 PPARG (0.51) PPARGMPC2CYP2C8CYP2C9MCL1
SCHEMBL19559725 0.75 PPARG (0.40) PPARGCYP2C9MCL1CYP3A4CYP1A2
SCHEMBL19559715 0.72 — —
SCHEMBL19217724 0.69 PPARG (0.39) PPARGHTTMPC2CYP2C8CYP2C9
SCHEMBL19559787 0.68 PPARG (0.50) PPARGMPC2CYP2C8CYP2C9MCL1
SCHEMBL19217761 0.68 PPARG (0.68) PPARGHTTMPC2CYP2C8CYP2C9
SCHEMBL19217752 0.67 PPARG (0.52) PPARGMPC2CYP2C8CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513070-B1 PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES CIRIUS THERAPEUTICS INC (US) 2017-11-08 — — EP disclosed
Send feedback